80223-99-0

Basic information

• Product Name: Tamsulosin hydrochloride
• Synonyms: Tamsulosinehydrochloride;Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, monohydrochloride (9CI);dl-Tamsulosin hydrochloride;(-)-(R)-5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide hydrochloride;Tamsulosin hydrochloride;Tamuzosin hydrochloride;EC-617;Racemic Tamsulosin Hydrochloride (50 mg)
• CAS NO: 80223-99-0
• Molecular Formula: C20H29ClN2O5S
• Molecular Weight: 444.97
• Product Categories: Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals
• Mol File: 80223-99-0.mol
• Article Data: 33

Chemical Properties

• Melting Point: 228-230℃
• Boiling Point: 595.5 °C at 760 mmHg
• Flash Point: 313.9 °C
• Appearance: /
• Vapor Pressure: 3.79E-14mmHg at 25°C
• CAS DataBase Reference: Tamsulosin hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Tamsulosin hydrochloride(80223-99-0)
• EPA Substance Registry System: Tamsulosin hydrochloride(80223-99-0)

Safety Data

• Hazardous Substances Data: 80223-99-0(Hazardous Substances Data)

Usage

Chemical Properties

White to Off-White Solid

Uses

Different sources of media describe the Uses of 80223-99-0 differently. You can refer to the following data:
1. Tamsulosin is a specific α1-adrenoceptor antagonist. Used in the treatment of benign prostatic hypertrophy.
2. Tamsulosin hydrochloride is a specific ;1-adrenoceptor antagonist. Used in the treatment of benign prostatic hypertrophy.

Clinical Use

Treatment of benign prostatic hyperplasia

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Antifungals: concentration increased by ketoconazole. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid concomitant use. Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension.

Metabolism

Tamsulosin is metabolised slowly in the liver primarily by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4; it is excreted mainly in the urine as metabolites and some unchanged drug

InChI:InChI=1/C20H28N2O5S.ClH/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24;/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24);1H

Upstream product

• 3250-73-5 2-(2-ethoxyphenoxy)ethanol 
• 169506-15-4 2-(2-ethyloxyphenoxy)ethyl methanesulfonate 
• 94666-07-6 5-[2-[2-(2-ethoxyphenoxy)-ethylamino]-2-methylethyl]-2-methoxybenzenesulfonamide 
• 122-84-9 4-methoxybenzyl methyl ketone 
• 104-01-8 4-Methoxyphenylacetic acid 
• 80223-79-6 2-methoxy-5-(2-oxopropyl)benzenesulfonyl chloride 
• 94-71-3 2-Ethoxyphenol 
• 86225-65-2 (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide hydrochloride 
• 3259-03-8 2-(o-ethoxyphenoxy)-ethyl bromide 
• 112101-81-2 5-((R)-2-amino-1-propyl)-2-methoxybenzenesulphonamide 
• 133261-17-3 (R)-2-(2-ethoxyphenoxy)-N-[2-(4-methoxy-3-aminosulfonyl-phenyl)-1-methyl-ethyl]-acetamide 
• 80223-99-0 (+/-)-Tamsulosin hydrochloride 
• 6781-17-5 2-(2-ethoxyphenoxy)-ethylamine 
• 116091-63-5 2-methoxy-5-(2-oxopropyl)benzenesulfonamide 

Relevant articles and documents

Continuous-Flow Synthesis of (R)-Tamsulosin Utilizing Sequential Heterogeneous Catalysis

We describe the continuous-flow synthesis of (R)-tamsulosin, a blockbuster therapeutic drug employed for dysuria associated with urinary stones and benign prostatic hyperplasia, by utilizing sequential heterogeneous catalysis. Two heterogeneous catalysts have been developed for the synthesis, and the key step involves reductive amination of nitriles using dimethylpolysilane-modified Pd on activated carbon/calcium phosphate. Overall, (R)-tamsulosin was obtained in 60 % yield and 64 % ee (99 % ee after recrystallization) in a flow stream through four catalytic transformations without the need for the isolation or purification of any intermediates or byproduct.

Preparation method of tamsulosin hydrochloride crystal form

The invention relates to the technical field of preparation of crystal forms of organic compounds, in particular to a preparation method of a tamsulosin hydrochloride crystal form. The method comprises the following steps: completely dissolving tamsulosin in a solvent at 60-70 DEG C, then dropwise adding acid for reaction for a period of time, conducting cooling to 20-30 DEG C, and conducting filtering, washing and drying to obtain tamsulosin, wherein tamsulosin is a refined product. The method is simple in process, high in yield, high in product purity and suitable for large-scale industrialization.

A high optical purity of tamsulosin preparation method of leach

The invention discloses a preparation method of tamsulosin hydrochloride with high optical purity, and belongs to a medicine technology and a chemical field. A recrystallization method is adopted, crude products of (R)-5-(2-(2-(2-ethoxyphenoxy) ethyl amino) propyl)-2-methoxyl phenyl sulfonamide hydrochloride are refined, so that pure products of the (R)-5-(2-(2-(2-ethoxyphenoxy) ethyl amino) propyl)-2-methoxyl group sulfonamide hydrochloride of which the e.e. value is larger than 99.8% is obtained; a crystallizing solvent adopted by the recrystallization method is a mixed solvent consisting of an organic solvent and water, the organic solvent is selected from one of methanol, ethyl alcohol, acetone, acetonitrile and isopropyl alcohol, and the recrystallization temperature is under 15 DEG C. The preparation method disclosed by the invention is simple to operate, short in period, low in cost and good in repeatability, and can solve the inevitable problem of rework for treatment in the industrial production.